{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:44:33Z","timestamp":1792788273646,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Genmab A\/S and AbbVie."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06798-4","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T03:48:09Z","timestamp":1770176889000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial"],"prefix":"10.1007","volume":"105","author":[{"given":"Yasmin H.","family":"Karimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Y.","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Roost","family":"Clausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umar","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Ghesquieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim M.","family":"Linton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tycel","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Vose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pegah","family":"Jafarinasabian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"D\u2019Angelo M\u00e5nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Soong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Steele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian W.","family":"Eskelund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hutchings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"6798_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G (2021) Diffuse large B-cell lymphoma. N Engl J Med 384:842\u2013858. https:\/\/doi.org\/10.1056\/NEJMra2027612","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"6798_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/hon.2847","volume":"39","author":"K Wienand","year":"2021","unstructured":"Wienand K, Chapuy B (2021) Molecular classification of aggressive lymphomas\u2014past, present, future. Hematol Oncol 39(Supplement 1):24\u201330. https:\/\/doi.org\/10.1002\/hon.2847","journal-title":"Hematol Oncol"},{"key":"6798_CR3","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U et al (2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130:1800\u20131808. https:\/\/doi.org\/10.1182\/blood-2017-03-769620","journal-title":"Blood"},{"key":"6798_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ajh.26151","volume":"96","author":"S Susanibar-Adaniya","year":"2021","unstructured":"Susanibar-Adaniya S, Barta SK (2021) Update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management. Am J Hematol 96:617\u2013629. https:\/\/doi.org\/10.1002\/ajh.26151","journal-title":"Am J Hematol"},{"key":"6798_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1182\/blood-2012-12-472027","volume":"122","author":"MJ Matasar","year":"2013","unstructured":"Matasar MJ, Czuczman MS, Rodriguez MA et al (2013) Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood 122:499\u2013506. https:\/\/doi.org\/10.1182\/blood-2012-12-472027","journal-title":"Blood"},{"key":"6798_CR6","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s00277-015-2467-z","volume":"94","author":"F Hitz","year":"2015","unstructured":"Hitz F, Connors JM, Gascoyne RD et al (2015) Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment. Ann Hematol 94:1839\u20131843. https:\/\/doi.org\/10.1007\/s00277-015-2467-z","journal-title":"Ann Hematol"},{"issue":"Supplement 1","key":"6798_CR7","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1182\/blood-2022-159702","volume":"140","author":"JS Abramson","year":"2022","unstructured":"Abramson JS, Solomon SR, Arnason JE et al (2022) Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) with salvage chemotherapy followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients with relapsed or refractory large B-cell lymphoma (LBCL): primary analysis of the randomized, phase 3 transform study. Blood 140(Supplement 1):1581\u20131583. https:\/\/doi.org\/10.1182\/blood-2022-159702","journal-title":"Blood"},{"key":"6798_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN (2023) Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol 20:359\u2013371. https:\/\/doi.org\/10.1038\/s41571-023-00754-1","journal-title":"Nat Rev Clin Oncol"},{"key":"6798_CR9","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA et al (2022) Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 386:640\u2013654. https:\/\/doi.org\/10.1056\/NEJMoa2116133","journal-title":"N Engl J Med"},{"key":"6798_CR10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1182\/bloodadvances.2023011992","volume":"8","author":"C Baguet","year":"2024","unstructured":"Baguet C, Larghero J, Mebarki M (2024) Early predictive factors of failure in autologous CAR T-cell manufacturing and\/or efficacy in hematologic malignancies. Blood Adv 8:337\u2013342. https:\/\/doi.org\/10.1182\/bloodadvances.2023011992","journal-title":"Blood Adv"},{"key":"6798_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00997-w","volume":"14","author":"A Trabolsi","year":"2024","unstructured":"Trabolsi A, Arumov A, Schatz JH (2024) Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas. Blood Cancer J 14:27. https:\/\/doi.org\/10.1038\/s41408-024-00997-w","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"6798_CR12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-194333","volume":"144","author":"M Dickinson","year":"2024","unstructured":"Dickinson M, Carlo-Stella C, Morschhauser F et al (2024) Fixed-duration glofitamab monotherapy continues to demonstrate durable responses in patients with relapsed or refractory large B-cell lymphoma: 3-year follow-up from a pivotal phase II study. Blood 144(Supplement 1):865. https:\/\/doi.org\/10.1182\/blood-2024-194333","journal-title":"Blood"},{"issue":"Supplement 1","key":"6798_CR13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-198714","volume":"144","author":"JM Vose","year":"2024","unstructured":"Vose JM, Cheah CY, Clausen MR et al (2024) 3-year update from the Epcore NHL-1 trial: epcoritamab leads to deep and durable responses in relapsed or refractory large B-cell lymphoma. Blood 144(Supplement 1):4480. https:\/\/doi.org\/10.1182\/blood-2024-198714","journal-title":"Blood"},{"key":"6798_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.102625","volume":"52","author":"PJ Engelberts","year":"2020","unstructured":"Engelberts PJ, Hiemstra IH, de Jong B et al (2020) DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine 52:102625. https:\/\/doi.org\/10.1016\/j.ebiom.2019.102625","journal-title":"EBioMedicine"},{"key":"6798_CR15","unstructured":"EPKINLY\u00ae (epcoritamab-bysp) (2025) [package insert]. Genmab US, Inc., Plainsboro, NJ, USA"},{"key":"6798_CR16","unstructured":"TEPKINLY\u00ae (epcoritamab-bysp) (2025) [summary of product characteristics]. AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany"},{"issue":"Supplement 1","key":"6798_CR17","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1182\/blood-2024-199708","volume":"144","author":"A Danilov","year":"2024","unstructured":"Danilov A, Fakhri B, Awan FT et al (2024) Epcoritamab monotherapy in patients (Pts) with relapsed or refractory (R\/R) chronic lymphocytic leukemia (CLL): results from CLL expansion and optimization cohorts of Epcore CLL-1. Blood 144(Supplement 1):883. https:\/\/doi.org\/10.1182\/blood-2024-199708","journal-title":"Blood"},{"key":"6798_CR18","doi-asserted-by":"publisher","unstructured":"Kater AP, Janssens A, Eradat H et al (2024) Single-agent Epcoritamab leads to deep responses in patients (pts) with richter\u2019s transformation (RT): primary results from the EPCORE CLL-1 trial. HemaSphere 8(Supplement 1):136. https:\/\/doi.org\/10.1002\/hem3.104","DOI":"10.1002\/hem3.104"},{"key":"6798_CR19","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/JCO.22.01725","volume":"41","author":"C Thieblemont","year":"2023","unstructured":"Thieblemont C, Phillips T, Ghesquieres H et al (2023) Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell\u2013engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J Clin Oncol 41:2238\u20132247. https:\/\/doi.org\/10.1200\/JCO.22.01725","journal-title":"J Clin Oncol"},{"key":"6798_CR20","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","volume":"38","author":"C Thieblemont","year":"2024","unstructured":"Thieblemont C, Karimi YH, Ghesquieres H et al (2024) Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial. Leukemia 38:2653\u20132662. https:\/\/doi.org\/10.1038\/s41375-024-02410-8","journal-title":"Leukemia"},{"key":"6798_CR21","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/jco.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133068. https:\/\/doi.org\/10.1200\/jco.2013.54.8800","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"6798_CR22","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.1182\/blood-2024-199477","volume":"144","author":"S Ayyappan","year":"2024","unstructured":"Ayyappan S, Prince HM, Carpio C et al (2024) Dynamics of complete responses in patients with relapsed or refractory diffuse large B-cell lymphoma treated with Odronextamab in the ELM-2 study. Blood 144(Supplement 1):4486. https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper199477.html","journal-title":"Blood"},{"key":"6798_CR23","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1182\/blood.2023020854","volume":"143","author":"JS Abramson","year":"2024","unstructured":"Abramson JS, Palomba ML, Gordon LI et al (2024) Two-year follow-up of lisocabtagene Maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001. Blood 143:404\u2013416. https:\/\/doi.org\/10.1182\/blood.2023020854","journal-title":"Blood"},{"key":"6798_CR24","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL et al (2017) Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377:2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"key":"6798_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/nejmoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380:45\u201356. https:\/\/doi.org\/10.1056\/nejmoa1804980","journal-title":"N Engl J Med"},{"key":"6798_CR26","doi-asserted-by":"publisher","unstructured":"Karimi Y, Thieblemont C, Ghesquieres H et al (2024) Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: subcutaneous epcoritamab monotherapy in patients with relapsed\/refractory large B-cell lymphoma (R\/R LBCL). J Clin Oncol 42:7039.\u00a0https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.7039","DOI":"10.1200\/JCO.2024.42.16_suppl.7039"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06798-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06798-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06798-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T11:34:39Z","timestamp":1772019279000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06798-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["6798"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06798-4","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"16 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yasmin H. Karimi reports consultancy for and honoraria from AbbVie and ADC Therapeutics; research funding from AbbVie, AstraZeneca, Lilly\/Loxo, Merck, Roche\/Genentech, and Xencor; and receiving travel expenses support from Roche\/Genentech. Chan Y. Cheah reports consultancy and advisory role for, or honoraria from AbbVie, AstraZeneca, BeiGene, BMS, CRISPR Therapeutics, Dizal, Genmab, Gilead, Janssen, Lilly, Menarini, Roche, Regeneron, and Sobi; speakers bureau participation for AbbVie, AstraZeneca, BeiGene, Genmab, Janssen, MSD, and Roche; research funding from AbbVie, BMS, Lilly, MSD, and Roche; and receiving travel expenses support from BeiGene and Lilly. Michael Roost Clausen reports advisory role for AbbVie, AstraZeneca, Genmab, Gilead, Incyte, Janssen, and Roche; and receiving travel expenses support from AbbVie, AstraZeneca, Genmab, Janssen, Pfizer, and Roche. David Cunningham reports research funding from 4SC, Bayer, Celgene, Clovis, Eli Lilly, and Roche. Umar Farooq reports membership on the Kite Pharma advisory board. Tatyana Feldman reports consultancy for AbbVie, AstraZeneca, Epizyme, Genmab, Gilead\/Kite, Karyopharm, Seagen, and Takeda; and speakers bureau participation for Seagen. Herve Ghesquieres reports consultancy for BMS, Roche, and Takeda; and honoraria from AbbVie, BMS, Gilead, Roche, and Takeda. Wojciech Jurczak reports consultancy for and research funding from AbbVie, AstraZeneca, BeiGene, Janssen Cilag, Lilly, Regeneron, Roche, and Takeda; and research funding from Merck, and MSD. Kim M. Linton reports research funding from AbbVie, BeiGene, BMS, Celgene, Genmab, Kite\/Gilead, and Roche; consultancy for AbbVie, BeiGene, BMS, Celgene, Genmab, and Kite\/Gilead; research support by the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (BRC) (NIHR203308); speakers bureau participation for AbbVie, BMS, and Celgene; receiving travel expenses support from Celgene, BMS; and membership on the Epcoritamab Global Council for Genmab. Catherine Thieblemont reports honoraria, consulting, or advisory role, and receiving travel\/accommodation expenses support from AbbVie, BMS, Roche, and Novartis. Tycel Phillips reports research funding (scholar in clinical research of The Leukemia & Lymphoma Society) from AbbVie, Bayer, Pharmacyclics\/Janssen, and Genentech, a member of the Roche Group; membership on an entity\u2019s board of directors or advisory committees for AbbVie, Genentech, a member of the Roche Group, Genmab, and Merck; honoraria from Lymphoma & Myeloma Connect, and Seattle Genetics; research funding from AbbVie and Genentech, a member of the Roche Group; consultancy for AbbVie, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene, BMS, Caribou, Epizyme, Genentech, a member of the Roche Group, Genmab, Gilead, Incyte, Lilly, and Pharmacy. Won Seog Kim reports research funding from BeiGene, Boryung, Dong-A, F. Hoffmann-La Roche Ltd, Kyowa Kirin, and Sanofi; and speakers bureau participation for Kumode, Janssen Pharmaceutical and Ono Pharmaceutical. Pegah Jafarinasabian reports being currently employed by and owning stocks in AbbVie. Barbara D\u2019Angelo M\u00e5nsson reports being currently employed by and owning stocks in Genmab. David Soong reports being currently employed by and owning stocks in Genmab. Andrew J. Steele reports being currently employed by Genmab and owning stocks in AbbVie, Genmab, and Johnson & Johnson. Zhu Li reports being currently employed by Genmab. Christian W. Eskelund reports being currently employed by Genmab. Martin Hutchings reports consultancy, advisory role for, or honoraria from AbbVie, AstraZeneca, Genmab, Johnson & Johnson, Merck, Roche, Takeda; and research support (paid to institution) from AbbVie, Arvinas, AstraZeneca, BMS, Celgene, Genentech, Genmab, Incyte, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, and Takeda. Julie M. Vose reports research study support from AbbVie, Genmab, Loxo, and Seagen; and consultancy for AbbVie, Genentech, and Genmab.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"79"}}